DelveInsight’s ’Multiple Myeloma (MM)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted MM epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
Multiple Myeloma (MM) Understanding
According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74.
Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow. Treatment for multiple myeloma usually includes anti-myeloma medicines to destroy the myeloma cells or control cancer when it comes back (relapses) and medicines and procedures to prevent and treat problems caused by myeloma – such as bone pain, fractures, and anemia.
Epidemiology Perspective by DelveInsight
The MM epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries. The MM epidemiology data are studied through MM possible division to give a better understanding of the Disease scenario in the 8MM.
The disease epidemiology covered in the report provides historical as well as forecasted MM epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of MM, Total Incident Cases of MM Segmented by Gender, Total Incident Cases of MM Segmented by Age, Total Cases of MM by Line of Treatment] scenario of MM in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030.
MM Detailed Epidemiology Segmentation

  • In the year 2017, the total incident case of Multiple Myeloma was 85,971 cases in the 8MM. The United States, in 2017, accounted for 30,271 cases (the highest number), which will probably rise by the year 2030.
  • Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma was in Germany 7,337, in the year 2017. In the year 2017, the total incident cases of Multiple Myeloma was 7,504 in Japan. In the year 2017, the total incident cases of Multiple Myeloma was 19,536 in China, which might increase cases by 2030.
  • In China, the total incident cases of Multiple Myeloma was 19,536 in 2017.
  • In 2017, the 8MM total symptomatic cases of Multiple Myeloma was 75,679. In addition to this, the United States, in 2017, accounted for 26,647 cases.
  • In gender-specific cases of Multiple Myeloma, males are frequently affected by Multiple Myeloma (accounted for approximately 55% of cases) in comparison to females.
  • In age-specific cases of MM, in 2017, the most number of cases were seen in the age-group 65–74, followed by the age-group of 75–84 years, and 55–64 years.
  • In the 8MM, the total cases of Multiple Myeloma by treatment line were 22,124 cases for frontline transplant eligible patients, 46,676 cases for frontline transplant ineligible patients, 42,244 cases for second-line patients, 22,092 cases for third-line patients, and 9,629 cases for fourth-line plus patients, in the year 2017


Scope of the Report

  • The MM report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The MM Report and Model provide an overview of the risk factors and global trends of MM in the seven major markets (8MM: United States, Germany, France, Italy, Spain, and the United Kingdom, Japan, and China).
  • The report provides insight about the historical and forecasted patient pool of MM in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan and China, and China.
  • The report helps to recognize the growth opportunities in the 8MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of MM.
  • The report provides the segmentation of the MM epidemiology by total Incidence of MM in the 8MM.
  • The report provides the segmentation of the MM epidemiology by total symptomatic cases of Multiple Myeloma in the 8MM.
  • The report provides the segmentation of the MM epidemiology by Age and Gender in the 8MM.
  • The report provides the segmentation of the MM epidemiology by Line-wise Treated Patient Pool of MM in the 8MM.



Report Highlights

  • 11-Year Forecast of MM epidemiology
  • 8MM Coverage
  • Total Incident Cases of Multiple Myeloma in the 8MM
  • Total Symptomatic Incident Cases of Multiple Myeloma in the 8MM
  • Incident Cases of MM according to segmentation: Age, and Gender
  • Treated cases of MM


KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over MM scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 8MM with respect to the patient population pertaining to MM ?
  • What are the key findings pertaining to the Multiple Myeloma epidemiology across the 8MM and which country will have the highest number of patients during the study period (2017–2030)?
  • What would be the total number of patients of Multiple Myeloma across the 8MM during the study period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
  • At what CAGR the patient population is expected to grow in the 8MM during the study period (2017–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Multiple Myeloma?



Reasons To Buy
The MM Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global MM market
  • Quantify patient populations in the global MM market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MM therapeutics in each of the markets covered
  • Understand the magnitude of MM population by its severity
  • The MM epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The MM Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China


Study Period: 2017–2030
Total Incident cases of MM in the United States was assessed to be 30,271 in 2017, and are expected to decline during the study period. Among the European 5 countries, the highest number of incident cases of Multiple Myeloma were in Germany 7,337, in the year 2017